Skip to main content
Equibles
NAMS logo

NAMS · NewAmsterdam Pharma Co N.V.

Track NAMS — free

Use NAMS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about NAMS

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$26.83 -1.04 (-3.73%)
Market Cap
$3.33B
Shares
119.54M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$27.87 Open$27.99 Day$27.66–28.35 52W close$23.95–41.45 Avg vol 30d1.1M Short int10.0M · 8.3% float · 9.8d Short vol67% Last earningsAug 5, 2026 DataFeb 2021–Aug 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Nov 4, 2026 Est · unconfirmed · in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 5, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.1 · calm Equity put/call 0.51
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −16%
below
Price vs 50-day avg −9%
below
RSI (14) 44
neutral
MACD trend Positive
52-week position 22%
mid-range
Momentum
relative strength
Very Weak
1-month return −6%
trailing
6-month return −15%
trailing
YTD return −21%
this year
Relative strength −27%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $31 › 200d $33 — 200d above 50d
Institutional flow Accumulating
+14% holders QoQ · +47 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
8.33% of float · ▲ +8.5% MoM · 9.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
200 holders — near 3-yr high, broad support
Squeeze score 72
high risk · 0–100
Fundamentals
Strong
Revenue growth −51%
Y/Y
EPS growth +33%
Y/Y
Balance sheet $490.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 56%
annualized · 1-yr
Max drawdown −36%
past year
ATR 4.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−16% Bearish
Price vs 50-day avg
−9% Bearish
RSI (14)
44 Neutral
MACD trend
Positive Bullish
52-week position
22% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $31 › 200d $33 — 200d above 50d
Institutional flow Accumulating
+14% holders QoQ · +47 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
8.33% of float · ▲ +8.5% MoM · 9.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
200 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $24 Now $28 · 22% Range high $41
vs 200-day avg -16% vs 50-day avg -9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
cash, cash equivalents and marketable securities $678.3M the quarter ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NAMS
NewAmsterdam Pharma Co N.V.
this stock
$3.33B -20.6% -50.6% — 8.3%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $138.91B +20.9% +46.2% 31.9 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $85.87B +8.1% +20.8% 20.7 3.3%
ARGX
Argenx SE
 $64.66B +23.6% — — 2.1%
CSLLY
Csl Ltd
 $57.97B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
200
% held
105.2%
Net QoQ
-115.5K sh
Top holder
Frazier Life Sciences Man…
Held Float
View
Held by Funds
Fund positions
28
View
Short & Settlement
Short Interest Rising
Shares short
10.0M
Days to cover
9.8d
Change
+783.3K sh
View
Short Volume
Short vol %
67%
As of
Aug 21, 2026
Short Total
View
Fails to Deliver
FTD shares
138
Value
$3.9K
As of
Jul 29, 2026
View
Off-Exchange
Off-exchange %
48.4%
Week of
Jul 20, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$22.5M
Net income (FY)
$-203.0M
EPS diluted
$-1.72
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 14, 2026
This year
17
View
Proposed Sales
Value
$1.4M
Shares
44.6K
Filed
Mar 11, 2026
View
Earnings & Events
Earnings Calls
Last call
Aug 5, 2026
View
Investor Relations
Latest news
NewAmsterdam Pharma Reports Induc…
Published
Aug 6, 2026
View

Performance

5D 20D 120D MTD YTD
NAMS +3.3% -6.0% -15.1% +0.3% -20.6%
SPY -1.4% +3.6% +11.6% +2.5% +12.3%
vs SPY +4.7% -9.6% -26.7% -2.2% -32.8%
Key facts CIK 1936258 CUSIP N62509109 13F (30d) 180 filings 176 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)